Kissei Of Japan Obtains U.S. FDA Approval For PBH Drug Silodosin

Japanese drug maker Kissei announced Oct. 9 that urination disorder drug Urief (silodosin) has obtained a new drug approval from U.S. FDA. Originally developed by Kissei, silodosin is an alpha 1A adrengergic receptor antagonist that improves the signs and symptoms of benign prostatic hyperplasia, such as weak stream and frequency and urgency of urination. In clinical studies, silodosin was shown to relieve symptoms faster compared to current products. Half of American males aged 60 years and over are estimated to have BPH. Silodosin will be marketed as Rapiflo in the United States (Click here for more - Japanese language